About Multiple Myeloma
Multiple myeloma is an abnormal growth of plasma cells found in the bone marrow. The cells ultimately infiltrate a number of organs and lead to organ failure, bone marrow destruction and failure. It is the most common tumor in the bone and the second most-common blood cancer in the U.S. and Europe. According to the American Cancer Society, estimates for multiple myeloma in the U.S. in 2016, were 30,000 new diagnoses, and more than 12,000 people were estimated to die from the disease. Most patients ultimately relapse from chemotherapy, and the disease is not considered curable using current approaches.
GMI-1271 is designed to block E-selectin (an adhesion molecule on vascular endothelial cells in the bone marrow) from binding with multiple myeloma cells. This is a targeted approach to disrupting well-established mechanisms of cancer cell resistance within the bone marrow microenvironment. Preclinical research points to our drug candidate’s potential role in moving cancerous cells out of the protective environment of the bone marrow where they hide and escape the effects of chemotherapy.
About the Phase 1 Clinical Trial in Multiple Myeloma
GMI-1271 has been tested in healthy volunteers, as well as in a Phase 1/2 clinical trial in patients with AML, and is now being studied in a multi-center Phase 1 clinical trial in Europe in patients with multiple myeloma. It is designed to evaluate GMI-1271’s safety, absorption by the body and effect on multiple myeloma when given with standard chemotherapy.